A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

NCT03290443 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene